Charles River Laboratories International, Inc. Share Price

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse 01:30:02 17/05/2024 am IST 5-day change 1st Jan Change
224.8 USD -3.36% Intraday chart for Charles River Laboratories International, Inc. -2.32% -4.93%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 4.22B 352B Sales 2025 * 4.53B 378B Capitalization 11.98B 1T
Net income 2024 * 406M 33.88B Net income 2025 * 513M 42.81B EV / Sales 2024 * 3.3 x
Net Debt 2024 * 1.94B 162B Net Debt 2025 * 1.46B 122B EV / Sales 2025 * 2.97 x
P/E ratio 2024 *
29.4 x
P/E ratio 2025 *
23.8 x
Employees 21,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.11%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Charles River Laboratories International, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260 MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $270 From $280 MT
Jefferies Adjusts Price Target on Charles River Laboratories International to $226 From $235 MT
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300 MT
Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282 MT
Transcript : Charles River Laboratories International, Inc., Q1 2024 Earnings Call, May 09, 2024
Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance MT
Charles River Laboratories International, Inc. Reports Impairment Charges for the First Quarter Ended March 30, 2024 CI
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024 CI
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q1 Adjusted EPS $2.27 MT
Stocks Down Pre-Bell Ahead of Latest Earnings Results; Asia, Europe Churn MT
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Posts Q1 Revenue $1.01B MT
(CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Expects Fiscal Year 2024 Adjusted EPS Range $10.90 - $11.40 MT
Charles River Laboratories International, Inc. Revises Financial Guidance for 2024 CI
More news
1 day-3.36%
1 week-2.32%
Current month-1.86%
1 month-3.27%
3 months-8.25%
6 months+18.56%
Current year-4.93%
More quotes
1 week
220.44
Extreme 220.44
238.22
1 month
220.44
Extreme 220.44
244.56
Current year
201.01
Extreme 201.01
275.00
1 year
161.65
Extreme 161.65
275.00
3 years
161.65
Extreme 161.65
460.21
5 years
95.58
Extreme 95.58
460.21
10 years
52.02
Extreme 52.02
460.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 01/76/01
Director of Finance/CFO 51 25/22/25
Chief Operating Officer 54 01/89/01
Members of the board TitleAgeSince
Director/Board Member 76 01/03/01
Director/Board Member 68 01/19/01
Director/Board Member 61 25/11/25
More insiders
Date Price Change Volume
17/24/17 224.8 -3.36% 1 301 402
15/24/15 232.6 -0.11% 529,498
14/24/14 232.8 +1.93% 502,307
13/24/13 228.4 +0.13% 447,273
10/24/10 228.1 -0.86% 842,499

Delayed Quote Nyse, May 17, 2024 at 01:30 am IST

More quotes
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
232.6 USD
Average target price
265.6 USD
Spread / Average Target
+14.21%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW